ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer

Li, Na; Wang, Geng; Hou, Xin; Tai, Risheng; Huang, Shaogang; He, Zhize; Lei, Lei; Xu, Suling*; Yang, Shanru*哈尔滨医科大学; 1
International Immunopharmacology2022-7DOI: 10.1016/j.intimp.2022.108803
4被引11阅读
引用收藏
分享

摘要

Immunotherapy is an emerging method for the treatment of cancer. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune checkpoint pathways and release the body's anti-tumor immunity. They consist mainly of antibodies against cytotoxic T lymphocyte associated antigen-4 (CTLA-4), programmed death receptor 1 (PD-1), and programmed death ligand 1 (PD-L1). Although ICI therapy has been shown to be effective at treating cancer, it can also destroy immune tolerance and lead to organ toxicity. These unwanted side effects are known as immune related adverse events (irAEs). ICI treatment can also cause unconventional re-actions such as pseudoprogression and hyperprogression. Pseudoprogression looks like an increase in the tumor parenchyma but is actually a temporary inflammation in the tumor; hyperprogression refers to the acceleration of tumor growth after the start of immunotherapy. Understanding the mechanisms of these two phenomena and distinguishing their differences are necessary for the effective prevention and treatment of unconventional reactions.

学科与关键词

关键词
ICIsirAEsPseudoprogressionHyperprogression
相关
加载中…
  • Biomarkers related to immune checkpoint inhibitors therapy
    Li, Na; Hou, Xin; Huang, Shaogang; Tai, Risheng; Lei, Lei; Li, Siyu; Abuliz, Adina; Wang, Geng*; Yang, Shanru*Biomedicine and Pharmacotherapy, 2022, 147: 112470.被引 9
  • Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastases
    Gu, T.; Yang, H.; Shen, J.; Lin, A.; Zhang, J.; Luo, P.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
  • Evaluation of immune checkpoint inhibitors rechallenge after immune-related adverse events in patients with cancer
    Tang, X-R.; Li, R.; Zhao, F.; Wen, X.; Wang, Y-K.; Lv, R-X.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
查看全部 →

发表信息

论文状态
公开发表
期刊
International Immunopharmacology
发表日期
2022-07
卷期
第 108 卷
页码
108803
DOI
10.1016/j.intimp.2022.108803
语言
ENGLISH
期刊等级
2区
成果收录
SCIE

作者

  • L

    Li, Na (第一作者)

    1 · ningbo univ

  • W

    Wang, Geng

    ningbo univ · harbin med univ

查看全部 9 位作者收起作者
  • H

    Hou, Xin

    ningbo univ

  • T

    Tai, Risheng

  • H

    Huang, Shaogang

    harbin med univ

  • H

    He, Zhize

    harbin med univ

  • L

    Lei, Lei

    harbin med univ

  • X

    Xu, Suling (通讯)

    1 · ningbo univ

  • Y

    Yang, Shanru (通讯)

    harbin med univ · ningbo univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417